Monte Jade New England

2015_Annual_Event

2015 Annual Event


Monte Jade Science and Technology Association of New England (MJNE)
is a non-profit organization, established on May 22, 1992 by science and technology professionals in the New England area.

Currently, MJNE is in its 25th year and is part of the Global Monte Jade network along with other active chapters in the U.S. and overseas.  MJNE includes professionals with a wide variety of experiences and expertise in science, engineering, medical, legal and business, and has become an idea incubator to serve its community.

Brief History

Monte Jade’s was founded at Silicon Valley, CA in 1989 with the initial force to bring together the high-tech experts from the Bay Area and it’s neighboring cities.  “Monte Jade” was chosen to signify cross-cultural and technological foresight and excellence of the highest level.

Current State History

MJNE is part of the growing Monte Jade family; as of today, there is 14 active chapters around the world.

 

Board Members

CAROLYN HSU

President

Dr. Hsu is a senior project manager at Abbvie Bioresearch Center, a subsidiary of AbbVie, Inc.  She possesses fifteen years of experience in the biopharmaceutical industry, providing technical and regulatory support to development of biologic drug substances, and process improvement of active pharmaceutical ingredients.  She is good at making possibilities real by taking unprecedented tasks and creating pathways to accomplish objectives, promoting communication across divisions inclusively.  She has been recognized by her peers as a thorough, responsible and dedicated team player to achieve deliverables. Prior to joining AbbVie (formerly the pharmaceutical division of Abbott Laboratories), she was a research fellow in the infectious disease department at Brigham and Women’s Hospital/Harvard Medical School.

Dr. Hsu is active in a wide array of communities. She served as the president of Greater Boston Alumni Association of National Taiwan University in 2011. She organized the Sustainable Wellesley Expo and Symposium 2010 to promote the awareness of reducing greenhouse gas emission for the town of Wellesley. She had served as the president and president-elect of the Sigma Xi Scientific Society, Abbott Chapter in 2003-2005. She enjoys organizing workshops and symposiums. Dr. Hsu has served on the Board of Directors for Monte Jade New England since 2011.

CRYSTAL SUNG

Vice President

Crystal Sung is a Sr. Scientific Director, Head of Clinical Diagnostics at Sanofi Genzyme.  She has over 15 years of industry experience in biologics clinical development with scientific expertise in Rare Disease, Oncology and Immunology. Crystal holds a Ph.D. degree in Pathology from The Ohio State University, College of Medicine and a BS in Medical Technology from National Taiwan University.  She completed her post-doctoral trainings at Northwestern University Medical School followed by Clinical Immunology Fellowship at Children’s Memorial Hospital.  Prior to joining Biotech/Pharma industry, she was an Assistant Professor in Tzu-Chi Medical School, Taiwan. Crystal is a member of AAPS, AMLI and AACC. She is AAPS TPIFG pre-existing antibody working group and ADA Clinical Relevance APA team.

Crystal Sung is a Diplomate of American Board of Medical Laboratory Immunology (ABMLI) and currently holds CLIA high complexity lab directorship and New York State Department of Public Health certificate of laboratory director in Diagnostic Immunology and Clinical Chemistry.  Crystal serves as Board of directors, Vice President of Mount Jade Science and Technology Association of New England.

MEI-HSIU LING

Director

Dr. Mei-Hsiu Ling is a Senior Director of Biometrics at Vertex. Dr. Ling received a B.S in Math from National Tsing Hua University and a Ph.D. In Statistics from U.C. Berkeley. She then started working in the pharmaceutical industry. Prior to Vertex, she worked at Schering-Plough and Novartis. She has been involved in late phase drug development, including antibiotics, antiviral (HCV, HIV), anti fungal, and respiratory (Asthma, COPD, Cystic Fibrosis). At Vertex, she is the Cystic Fibrosis statistics franchise head responsible for all statistical support for Cystic Fibrosis drug development. She is also the acting department head for the statistical programming group.

JAIME TSUNG

Director

Dr. Jamie Tsung is a principal scientist with in product development and processing in the biopharmaceutical industry. Currently, she works for Momenta Pharmaceuticals. Prior to Momenta, she worked at Shire where her research is focused on product development for the CNS (Central Nervous System).

SHERRY LEE

Director

Dr. Sherry Lee is currently a postdoctoral researcher at the Whitehead Institute for Biomedical Research, which is closely affiliated with MIT. She has been conducting basic research to understand the molecular mechanisms of red blood cell development, as well as translational research to develop technologies to benefit patients in need of blood transfusion.

Dr. Lee received her Ph.D. in Biomolecular Chemistry from University of Wisconsin-Madison, M.A. in Medical Sciences from Boston University and B.S. from National Cheng Kung University in Taiwan.

Besides exploring biology of red blood cells, Dr. Lee has been active in organizing events and serving various communities, including National Cheng Kung University Alumni Association New England, Boston Taiwanese Biotech Association, and MIT Biology IAP. She has served as a board director of Monte Jade New England since 2012.

PO-SHUN LEE

Director

Dr. Po-Shun Lee has been serving as Proteostasis’ Executive Vice President since December 2015 and Chief Medical Officer since June 2015. He also served as Senior Vice President, Clinical Development from June 2015 to December 2015 and as Vice President, Clinical Development from November 2014 to June 2015. From February 2013 to November 2014, he served as Translational Medicine Expert at the Novartis Institute for Biomedical Research. From August 2010 to January 2013, Dr. Lee served as the Associate Medical Director at Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) where he supported the clinical development and registration of Kalydeco and led a CFTR corrector program to positive proof of concept. From June 2005 to August 2010, Dr. Lee served as a physician-scientist at the Brigham and Women’s Hospital/ Harvard Medical School. He received an M.D. from the University of Pennsylvania and a B.A. in Biology from the Johns Hopkins University.

VICTOR TANG

Director

Victor was a corporate  executive in key IBM strategic initiatives. In 1997, he led the strategy for shifting IBM from hardware to services. He was also appointed the first Director General of the China-IBM Technology Cooperation Committee.  Victor has advised Fortune 100 companies and  governmental organizations including Taiwan, Finland, and the Economic Forum.

HSIN-HAO SU

Director

Dr. Hsin-Hao Su is an associate Professor of Mathematics at Stonehill College. He obtained his PhD in mathmatics from Johns Hopkins University. His research interest is Homotopy Theory, Algebraic Algebra, and Graph Theory.

LIH-LING LIN

Director

Dr. Lih-Ling Lin is a Senior Director, Inflammation and Immunology Research Unit, Pfizer. Dr. Lin graduated from National Taiwan University with a undergraduate degree in Pharmacy and Master degree in Biochemistry. She then went to University of Arizona for her graduate work. After receiving her PhD degree in Biochemistry, She joined Wyeth (Genetics Institute) and contributed to the discovery of several PLC and cPLA2 family members. She then led a discovery team targeting the signal transduction pathways in innate immunity involved in the production of inflammatory mediators and cytokines (e.g. TNF). These projects include development of kinase inhibitors and Biologics targeting innate receptors. This effort has led to the discovery of clinical candidates in treating autoimmune and inflammatory diseases such as rheumatoid arthritis and Inflammatory Bowel disease. Dr. Lin currently is leading the Exploratory Innate Immunity group dedicated in the emerging science for the drug discovery effort in the Inflammation and Immunology Research Unit. Dr. Lin is an author of over 70 scientific papers and patents.

Sheng-Ying Pao

Director

Dr. Sheng-Ying (Aithne) Pao currently serves as a Director of Strategic Innovation at Lee Kum Kee Group. Pao leads diverse teams. developed strategies, initiated partnerships, and drove product teams to expand the 128-year-old sauce company into a digital tech business. Prior to that, Pao co-founded startup teams. She created design solutions and shaped go-to-market strategy for startups; one of which achieved 15-times its Kickstarter goal. She has consulted on innovation strategy for startups, reviewed, and judged competitions including IDEAS Global Challenge.

Her interdisciplinary background spans three areas: design, marketing, and engineering. Pao received her Ph.D. from MIT Media Lab focusing on interaction design, gesture sensing, and immersive experience. She was named MIT Cisco Fellow for two consecutive years. Pao is also government certified in international trading and marketing by the Taiwan External Trade Development Council. Her profession in design, marketing, and engineering represents the future trend of interdisciplinary science and technology.  With her interdisciplinary experience, she was invited to co-lead and lecture at MIT graduate courses and to teach professional workshops for organizations such as the Tribeca Film Institute.

LISA KANG

Director

Lisa is a senior director of biometrics at Proteostasis Therapeutics. Lisa is from Taiwan and holds a Bachelor of Science in Chemistry from the University of North Carolina at Chapel Hill and a Masters in Biostatistics from Tulane University. She has held statistical consulting positions in several pharmaceutical and biotechnology companies including Pfizer, Genzyme, GlaxoSmithKline, Eli Lilly and Eisai in the past 16 years. Lisa’s interest is to streamline clinical development process and minimize cost in the drug development. She has published several papers in peer-reviewed medical journals.

JENG-SHIN LEE

Director

Dr. Jeng-Shin Lee is the Chief Scientific Officer at AB Biosciences, Inc. Founded in 2007, AB Biosciences Inc. (ABB) is a development stage biotechnology company, seeking to apply its proprietary technologies in protein and antibody engineering, to a selected group of important druggable target proteins, with the ultimate goal of generating novel antibody molecules for diagnostic and therapeutic purposes.

Y.JENNY CHEN

Director

Dr. Jenny Chen is a Shareholder of Wolf Greenfield & Sacks, P.C., a Boston-based law firm specialized in intellectual property law.  Jenny focuses her practice on U.S. and foreign patent prosecution and portfolio strategy, opinion work, due diligence, and post-grant matters such as interference, inter partes review, and reexamination.  Jenny counsels clients in the areas

of biological, medical, and pharmaceutical sciences.  She has worked on projects related to biosimilars, diagnosis and treatment for various diseases, vaccine technologies, drug discovery, antibiotic biosynthesis, medical implants, gene- and cell-based therapies, pharmaceutical formulations, and herb extracts.  Jenny has repeatedly been named one of Massachusetts Super

Lawyers’ “Rising Stars” in the field of intellectual property law.

Prior to practicing patent law, Jenny was a postdoctoral fellow at Brigham & Women’s Hospital, Harvard Medical School.  Her research focused on T cell activity in autoimmune diseases such as Type I diabetes.

Jenny received her J.D. from Northeastern University School of Law, her Ph.D. from Baylor College of Medicine, and her B.S. from Fudan University.   She is a member of the State Bar of Massachusetts and is registered to practice before the U.S. Patent and Trademark Office.  She is also a member of the American Intellectual Property Law Association and Boston Patent Law Association.

YING SUN

Director

Dr. Ying Sun is a professor at University of Rhode Island. Professor Ying Sun is a great role model, enthusiastic, thoughtful, caring, and well respected in his professional community. He has been a faculty member of the University of Rhode Island since 1985. He has developed and taught several courses in the Biomedical Engineering area.

HANK HUNGYUN LIN

Director

Dr. Hungyun Hank Lin is currently a Principal Scientist of Pfizer in Cambridge, MA. He represents drug safety within project teams in multiple therapeutic areas; and provides development and assessment of integrated biomarkers in support of both efficacy and toxicity biomarker needs in drug discovery and safety. Hank received his M.S. in Toxicology from National Taiwan University and his Ph.D. in Pathology and Laboratory Medicine from University of Rochester Medical School where he initiated his professional interests in metabolic syndrome and reproductive endocrinology.

Prior to joining Pfizer, Hank has held positions in several biomedical companies including Taiwan Biotech Co., Vaxin, AstraZeneca; providing expertise and technical skills for developing strategic initiatives of integrated biomarkers assessing mechanistic insight of target organ toxicities. He has published papers in basic and applied pathology, molecular toxicology, and endocrinology.

SEAN YI-HSIANG HSU

Director

Dr. Sean Yi-Hsiang Hsu is a Co-director and Assistant Professor at Harvard Medical School, Associate Member at BROAD Institute of MIT and Harvard. He is also an Assistant Professor at Program for Quantitative Genomics, Program of Molecular and Integrative Physiological Sciences, Harvard School of Public Health, Boston, MA.

His research focuses on (1) genetic contribution of common aging relevant disorders (such as osteoporosis, sarcopenic obesity, metabolic syndrome, type 2 diabetes and hypertension) using population-based next generation whole genome
sequencing, exome-sequencing and GWAS approaches; (2) statistical method development on multiple-phenotype association analyses; (3) integrative omics dataset using system genetics and bioinfomatic approaches and (4) identifying biomarkers of osteoporosis using
metabolomics.

ANDREW HO

Director

Dr. Andrew Ho is currently executive director at SK Life Science, a subsidiary of SK Group. He received Medical Degree from University of California, San Diego. He pursued an academic career after psychiatry residency and was Associate Professor at UCLA, where his research areas were schizophrenia, addiction, and bioinformatics.

Dr. Ho began his pharma career in 2007 at Merck. Since that time, he has been leading early and late phase drug development projects at Merck, Amgen, Takeda, and Forum Pharma.

LEON CHEN

Director

Leon Chen is a serial entrepreneur focus on healthcare technology in the U.S., China, and Taiwan market, providing strategy skill, inter-market insight and software knowledge for the businesses he co-founded. Started as a software engineer, Leon entered the healthcare startup named U-ARK Tech. with many projects experience such as remote clinical research of Arad County Clinical Hospital, Cardiology telehealth project of National Taiwan University Hospital and eventually become the founder of U-ARK America, Inc. a U.S. branch of U-ARK Tech. to lead a team of 11 to adapt the Taiwanese software technology to the U.S. market. After successfully establish early clients, Leon was invited to join G3iHealth Llc. an ITRI spun-off healthcare tech startup in Beijing where he is planning to apply Artificial Intelligence to enhance the care outcome and response time for the business.

 

Officers

Carolyn Hsu –President

Crystal Sung – Vice President

Patti Huang –Public relationship officer

Chih-Chieh Wang –Annual event coordinator

Leon Chen – IT officer

Hao-Wei Su –IT officer

Yafen Kang – Marketing officer

Yao-Hao Chen– Marketing officer